Biogen board slashes CEO's bonus as business struggles; how drugmakers could handle insulin prices

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Biogen board slashes CEO's bonus as Aduhelm sales and overall business struggle By Adam Feuerstein and Damian Garde Steven Senn/AP CEO Michael Vounatsos has presided over the volatile development of the Alzheimer's drug Aduhelm and its disastrous commercial rollout. Read More STAT+: U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency By Ed Silverman Adobe The U.S. Trade Representative claims a European Medicines Agency policy may disclose industry trade secrets contained in clinical study reports. Read More STAT+: Would drugmakers lower their insulin prices if Congress asks nicely? By Rachel Cohrs KEREM YUCEL/AFP via Getty Images Two senators have a new idea to slash insulin costs: dangling incentives to convince drugmakers to lower prices of their own free will. Read More Sponsor content by STAT Events May 24 | The STAT Health Tech Summit Join us virtually, or in San Francisco, as we convene experts from Amazon Lab126, Ascension, Google Health, and more to discuss the next big innovations in health tech. We'll cover everything from patient data to AI to telemedicine. Learn more at statnews.com/summit. STAT+: Startups are turning to a century-old technology to fuel a resurgence in neuro drug development By Allison DeAngelis Oli Scarff/Getty Images Biotechs are used to turning to genetics as guideposts in developing new medications. Now some are turning to a century-old technology. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Opinion: HHS needs to step up so CDC's new guidelines won't be 'a bridge to nowhere' for most Americans living with chronic pain By Shravani Durbhakula and Joshua M. Sharfstein Adobe The CDC's pain treatment guidelines will likely recommend comprehensive options that will be available to only a minority of Americans. Read More Friday, April 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser